ArticleNew microbes and new infections2026
Efficacy and safety of colistin monotherapy versus colistin-based combination therapy in pediatric patients with multidrug-resistant gram-negative infections: A propensity score analysis.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the efficacy and safety of colistin monotherapy versus colistin-based combination therapy in pediatric patients with multidrug-resistant Gram-negative bacteria (MDR-GNB) infections. Methods: This retrospective cohort analysis encompassed patients under the age of 18 years diagnosed with MDR-GNB infections who were administered intravenous colistin at Chiang Mai University Hospital during the period from 2010 to 2024. Inverse probability weighting (IPW) utilizing propensity scores was employed to equilibrate baseline characteristics. The primary endpoint was defined as 30-day mortality. Secondary endpoints comprised end-of-treatment mortality, clinical response, microbiologic response, and nephrotoxicity. Both univariable and multivariable logistic regression analyses were conducted subsequent to the implementation of propensity score weighting via IPW. Results: Colistin alone and combination therapy did not substantially affect 30-day mortality among 218 patients (74 monotherapy and 144 combination therapy) (adjusted odds ratio [aOR], 2.50; 95% confidence interval [CI], 0.69-9.15; p = 0.165). Clinical response (aOR, 1.27; 95% CI, 0.52-3.10; p = 0.595), end-of-treatment mortality (aOR, 0.79; 95% CI, 0.32-1.91; p = 0.595), and nephrotoxicity rate (aOR, 0.93; 95% CI, 0.40-2.17; p = 0.867) did not show any significant differences. When compared to monotherapy, patients receiving colistin-based combination therapy had a significantly greater microbiologic response rate (aOR, 3.62; 95% CI, 1.08-12.10; p = 0.037). Conclusions: Colistin-based combination therapy improved microbiologic response but showed no mortality or safety advantage over monotherapy in pediatric patients with MDR-GNB. Colistin monotherapy may provide comparable clinical outcomes without increased toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.